A hepatitis C virus (HCV) internal ribosome entry site (IRES) domain III-IV-targeted aptamer inhibits translation by binding to an apical loop of domain IIId
被引:63
作者:
Kikuchi, K
论文数: 0引用数: 0
h-index: 0
机构:Natl Inst Adv Ind Sci & Technol AIST, Inst Biol Resources & Funct, Tsukuba, Ibaraki 3058566, Japan
Kikuchi, K
Umehara, T
论文数: 0引用数: 0
h-index: 0
机构:Natl Inst Adv Ind Sci & Technol AIST, Inst Biol Resources & Funct, Tsukuba, Ibaraki 3058566, Japan
Umehara, T
Fukuda, K
论文数: 0引用数: 0
h-index: 0
机构:Natl Inst Adv Ind Sci & Technol AIST, Inst Biol Resources & Funct, Tsukuba, Ibaraki 3058566, Japan
Fukuda, K
Kuno, A
论文数: 0引用数: 0
h-index: 0
机构:Natl Inst Adv Ind Sci & Technol AIST, Inst Biol Resources & Funct, Tsukuba, Ibaraki 3058566, Japan
Kuno, A
Hasegawa, T
论文数: 0引用数: 0
h-index: 0
机构:Natl Inst Adv Ind Sci & Technol AIST, Inst Biol Resources & Funct, Tsukuba, Ibaraki 3058566, Japan
Hasegawa, T
Nishikawa, S
论文数: 0引用数: 0
h-index: 0
机构:Natl Inst Adv Ind Sci & Technol AIST, Inst Biol Resources & Funct, Tsukuba, Ibaraki 3058566, Japan
Nishikawa, S
机构:
[1] Natl Inst Adv Ind Sci & Technol AIST, Inst Biol Resources & Funct, Tsukuba, Ibaraki 3058566, Japan
[2] Yamagata Univ, Fac Sci, Yamagata 9908560, Japan
The hepatitis C virus (HCV) has a positive single-stranded RNA genome, and translation starts within the internal ribosome entry site (IRES) in a cap-independent manner. The IRES is well conserved among HCV subtypes and has a unique structure consisting of four domains. We used an in vitro selection procedure to isolate RNA aptamers capable of binding to the IRES domains III-IV. The aptamers that were obtained shared the consensus sequence ACCCA, which is complementary to the apical loop of domain IIId that is known to be a critical region of IRES-dependent translation. This convergence suggests that domain IIId is preferentially selected in an RNA-RNA interaction. Mutation analysis showed that the aptamer binding was sequence and structure dependent. One of the aptamers inhibited translation both in vitro and in vivo. Our results indicate that domain IIId is a suitable target site for HCV blockage and that rationally designed RNA aptamers have great potential as anti-HCV drugs.